Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amgen, Daiichi Sankyo, Genelux, Replimune, Binhui Biopharma
The Oncolytic Virus Therapies market is projected for strong growth through 2034, driven by increasing cancer prevalence and advancements in biotechnology. Key companies like CG Oncology, Imugene, and Amgen are developing various therapies, with several receiving FDA designations and progressing through clinical trials. The report highlights RP1 (Replimune Inc.) for advanced melanoma and discusses market drivers and barriers for this emerging cancer treatment approach.
Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares
Replimune Group (NASDAQ:REPL) insider Christopher Sarchi sold 6,500 shares of the company's stock on April 2nd at an average price of $8.01, totaling $52,065. This transaction reduced his ownership by 4.11% to 151,588 shares and was conducted under a pre-arranged Rule 10b5-1 trading plan. The company, a clinical-stage biotech focused on oncolytic immunotherapies, currently has a consensus "Hold" rating from analysts with an average target price of $10.00.
Replimune (NASDAQ: REPL) CCO sells 6,500 shares under 10b5-1 plan
Replimune Group, Inc.'s Chief Commercial Officer, Christopher Sarchi, sold 6,500 shares of common stock at a weighted average price of $8.01 per share on April 2, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025. Following the sale, Sarchi still beneficially owns 151,588 shares and holds options for an additional 250,425 shares, with 142,555 of them currently exercisable, indicating a continued significant equity interest in the company.
Replimune group’s CCO Sarchi sells $52k in stock
Christopher Sarchi, Chief Commercial Officer of Replimune Group (NASDAQ: REPL), sold 6,500 shares of common stock for $52,065 on April 2, 2026, through a pre-arranged trading plan. Despite the sale, Sarchi retains significant holdings in the company with 151,588 shares and options for 250,425 more. Replimune's stock has since risen, and analysts maintain a positive outlook with price targets between $10 and $19.
Replimune Shares Face Pivotal FDA Decision on RP1 Therapy
Replimune Group Inc. is at a critical juncture as the FDA is set to decide on its immunotherapy candidate, RP1, by April 10. The decision will significantly impact the company's financial stability and commercial strategy, especially given a previous rejection in July 2025 and a subsequent resubmission based on IGNYTE clinical trial data. Investors are anticipating high stock volatility.
Replimune Shares Face Pivotal FDA Decision on RP1 Therapy
Replimune Group Inc. is awaiting a critical FDA decision on its lead immunotherapy candidate, RP1, for advanced melanoma, with the regulatory review concluding on April 10. The outcome will significantly impact the company's stock volatility, financial stability, and commercial launch plans, as the company previously faced a setback and later resubmitted its application with additional clinical data. Investors are closely watching as this decision will determine the future trajectory of Replimune's medical impact and financial standing.
Replimune Sees Positive Momentum Amid Strategic Developments
Replimune Group Inc. (NASDAQ: REPL) has seen its stock rise by 10.78% due to strategic developments, partnerships, and a strong cash position, despite facing significant financial challenges like negative EBITDA and net income. Analysts are cautiously optimistic about its growth potential, highlighting R&D investments and a recent strategic acquisition, while noting the need for improved operational efficiency and breakthrough innovations. The company's financial health shows robust liquidity but also a moderate debt level, making future strategic financial planning crucial for its ascent in the biotech sector.
Replimune Stock Soars Amidst Strategic Developments and Financial Innovation
Replimune Group Inc. (NASDAQ: REPL) stock has risen by 10.78% following promising FDA breakthroughs and strategic financial developments. The company shows strong liquidity but faces challenges with negative earnings and free cash flow. Despite a cautious overall outlook, the stock's recent upward momentum and strategic collaborations suggest potential for future growth in the biotech sector.
REPL PE Ratio & Valuation, Is REPL Overvalued
The article analyzes Replimune Group Inc (REPL) valuation, indicating it is currently in the "Fair zone." Its forward P/S ratio of 10.55 is considered fair compared to its five-year average, with a fair price estimated between $4.42 and $37.75. The company's P/B ratio and negative FCF yield are also discussed in relation to historical averages and industry benchmarks.
Replimune, Grace among biotechs with April PDUFA dates
The FDA has at least eight PDUFA dates scheduled for April, including a decision on an oncolytic virus from Replimune Group Inc. While the Center for Biologics Evaluation and Research (CBER) had two decisions planned for April, the ruling on Orca-T from Orca Biosystems Inc. has been delayed to July 6. The article notes that Orca Biosystems updated CMC data in response to an FDA request.
REPL files Form 144 notice (NASDAQ: REPL) with RSU vesting details
Replimune Group (NASDAQ: REPL) has filed a Form 144 notice with the SEC, detailing proposed sales of common shares via J.P. Morgan Securities LLC. The filing, dated April 2, 2026, includes scheduled RSU vesting entries on November 15, 2023, November 15, 2024, and November 15, 2025, with specified share amounts. A Form 144 is a procedural notice of intent to sell and does not confirm completed transactions.
Replimune Shares Approach a Pivotal Regulatory Verdict
Replimune Group Inc. is nearing a critical regulatory decision from the FDA regarding its cancer therapy RP1, with a verdict expected on April 10. The company has secured an immediate $35 million in funding and potentially an additional $120 million, extending its financial runway through Q1 2027. Market activity has significantly increased, reflecting investor speculation ahead of the high-stakes announcement, which follows a prior complete response letter from the FDA.
Replimune Group (FRA:7R8) PB Ratio : 2.79 (As of Mar. 28, 2026)
This article provides an analysis of Replimune Group's (FRA:7R8) Price-to-Book (PB) Ratio, which is reported as 2.79 as of March 28, 2026. The company has a GF Score of 40/100 and ranks better than 50.4% of Biotechnology companies on this metric, despite a warning sign for investors. The article details the calculation of the PB Ratio, its historical trends, and compares it to industry peers and the Biotechnology sector median.
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts
Analysts have rated Replimune Group, Inc. (NASDAQ:REPL) with a consensus "Hold" rating, based on recommendations from ten analysts with an average 12-month price target of $10.00. The sentiment is mixed, with some analysts raising price targets and others reissuing a "sell" rating. The company recently reported better-than-expected quarterly earnings per share and institutional investors have been actively trading its stock.
Replimune's Oncolytic Viral Therapy For Melanoma Faces Second Shot At FDA Approval
Replimune Group Inc. (REPL), a clinical-stage biotechnology company, has an upcoming FDA decision for its lead investigational product, RP1, on April 10, 2026. RP1, an oncolytic therapy derived from a genetically engineered herpes simplex virus, is being investigated in combination with Bristol Myers Squibb's Opdivo for advanced melanoma. The article notes that further content is premium and requires a subscription.
Replimune Shares Skyrocket After FDA Accepts Resubmitted BLA for Melanoma Therapy
Replimune Group Inc. shares surged significantly after the FDA accepted the resubmitted Biologics License Application (BLA) for its lead investigational therapy, RP1, in treating cutaneous melanoma. A PDUFA date of October 25, 2026, has been assigned for the FDA's decision. This positive development follows a complete response letter issued in February, addressing chemistry, manufacturing, and controls (CMC) deficiencies, which Replimune has since resolved.
Institutional Investors Double Down on Replimune Amid Market Turmoil ()
Amid market volatility and downward trends in major US indices, large institutional investors are showing divergent strategies regarding Replimune Group. While some, like Braidwell LP and Quinn Opportunity Partners, are significantly increasing or initiating stakes in the biotechnology firm, others, such as Boxer Capital Management, are reducing their holdings. This clash of strategies highlights the biotech sector's sensitivity to clinical milestones and regulatory progress, with the stock's future movements heavily dependent on operational updates from ongoing clinical studies and overall risk appetite for healthcare stocks.
Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL
Boxer Capital Management LLC significantly reduced its stake in Replimune Group, Inc. (NASDAQ:REPL) by 52.5% in the third quarter, now holding 1.05 million shares valued at $4.40 million. Despite Boxer Capital's reduction, several other large funds, including Readystate Asset Management, Braidwell LP, Balyasny Asset Management, Erste Asset Management, and UBS Group AG, substantially increased their positions in REPL. Institutional investors collectively own approximately 92.53% of the company's stock, which currently trades around $7.14 with a market capitalization near $590 million and a consensus "Hold" rating from analysts.
Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL
Braidwell LP significantly increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 550.3% in the third quarter, now owning 2,750,092 shares valued at $11.523 million. Other institutional investors like Erste Asset Management and Readystate also made substantial purchases, leading institutional investors to hold about 92.53% of the company's stock. Despite mixed analyst ratings, Replimune Group recently surpassed quarterly EPS estimates.
Replimune Stock Quote, Share Price, News and Analysis
This article provides financial information and news updates for Replimune (REPL.US), including stock quotes, recent earnings reports for various fiscal periods in 2025 and 2026, and clinical trial news. It details the company's revenue and EPS figures, as well as announcements regarding its IGNYTE Clinical Trial and research documents. The page also includes a list of top-gaining stocks.
REPL Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive overview of Replimune Group's (REPL) financial statements, including its income statement, balance sheet, and cash flow statement, derived from SEC filings up to fiscal year 2025. It highlights key financial metrics such as negative net income, EBITDA, and free cash flow, alongside assessments of financial health signals like a weak Piotroski F-Score and low earnings quality. The report also details historical financial data, various financial ratios, and answers frequently asked questions about the company's profitability and financial standing.
Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions?
Wall Street analysts project a potential 79.6% surge for Replimune Group (REPL), with an average short-term price target of $12.86. Despite the inherent risks and skepticism surrounding analyst forecasts, strong consensus and upward revisions in earnings estimates, coupled with a Zacks Rank #2 (Buy), suggest potential for near-term upside. Investors are cautioned to use price targets as a starting point for deeper research rather than the sole basis for investment decisions.
Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions?
Shares of Replimune Group (REPL) have seen a recent increase, and Wall Street analysts project a potential gain of 79.6% from current levels, with an average short-term price target of $12.86. Despite a wide range in individual analyst targets, there is strong consensus on the company's positive earnings outlook and upward revisions in EPS estimates, leading to a Zacks Rank #2 (Buy). Investors are advised to consider these predictions cautiously and combine them with further fundamental research.
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?
Replimune Group (REPL) shares have gained 2.7% recently, but Wall Street analysts predict a potential upside of 79.6% from its current price of $7.16, with a mean price target of $12.86. This optimism is further supported by strong agreement among analysts in revising EPS estimates higher, and the stock currently holds a Zacks Rank #2 (Buy). While price targets themselves can be misleading, the consensus on earnings estimate revisions suggests legitimate upside potential.
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?
Shares of Replimune Group (REPL) have seen a 2.7% gain recently, with Wall Street analysts projecting a potential upside of 79.6% from its last closing price of $7.16, reaching a mean target of $12.86. While relying solely on price targets can be misleading, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) for REPL suggest a stronger likelihood of an upside. The company's earnings estimates for the current year have increased by 5% over the past month, with four upward revisions and no negative ones, indicating growing analyst optimism.
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. announced that its management team will present and host investor meetings at two upcoming investor conferences: the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, and the Jefferies 2026 Biotech on the Beach Summit on March 10, 2026. Live webcasts of the fireside chat will be available on Replimune's website, with replays available for 30 days. The company, a clinical-stage biotechnology firm, focuses on developing novel oncolytic immunotherapies.
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. announced that its management team will present and host investor meetings at two upcoming conferences: the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, and the Jefferies 2026 Biotech on the Beach Summit on March 10, 2026. The company is a clinical-stage biotechnology firm focused on developing novel oncolytic immunotherapies. Live webcasts of the fireside chat will be available on Replimune's website.
Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL
Erste Asset Management GmbH significantly increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 13,597.5% in Q3, holding 1,630,000 shares valued at approximately $7.07 million. Despite this institutional buying, several insiders, including Director Kapil Dhingra and CEO Sushil Patel, have recently sold shares. Analysts offer mixed ratings for REPL, with an average price target of $10.00, while the company reported better-than-expected earnings for its last quarter.
Replimune Group, Inc. - Common Stock (NQ: REPL
This article provides recent news headlines and stock market updates related to Replimune Group, Inc. (NQ: REPL). Key events include the FDA's rejection of Replimune's blood cancer drug application which significantly impacted its stock, and various market movements both before and during trading sessions involving REPL and other healthcare stocks. The report also highlights past financial news such as Replimune beating EPS estimates in Q1 2025 and positive clinical trial results for its melanoma treatment.
Forbion discloses 3.5% Replimune (REPL) stake in ownership filing
Forbion Capital Fund III Cooperatief U.A. and Forbion III Management B.V. have reported a beneficial ownership of 2,808,368 shares in Replimune Group, Inc., which represents approximately 3.5% of the company's outstanding common stock. This disclosure indicates that the reporting persons now hold 5% or less of the class, with shared voting and investment power over these shares. The filing is based on Replimune's 79,631,167 shares outstanding as of December 31, 2025.
Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP
Readystate Asset Management LP significantly increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 1,296.2% in Q3, purchasing over 2.4 million additional shares. This acquisition brings their total holdings to 2,621,012 shares, valued at approximately $10.98 million, representing about 3.36% ownership. Despite this increase in institutional ownership and several other hedge funds also adjusting their positions, Replimune's stock price recently dropped by 8.9%, opening at $7.26, and faces mixed analyst ratings with an average "Hold" consensus and an average target price of $10.00.
Replimune Group (REPL) director gifts 25,000 common shares
Replimune Group, Inc. director Philip Astley-Sparke reported a disposition of 25,000 shares of common stock through a bona fide gift, as detailed in an SEC Form 4 filing. The transfer was at a reported price of $0.00 per share, indicating it was a gift rather than a sale. Following this transaction, Astley-Sparke's directly held ownership stands at 1,380,071 common shares.
Institutional Confidence Surges in Replimune as Key Drug Review Looms
Replimune Group Inc. (REPL) shares surged over 13% following reports of significant new investments from institutional funds like Forbion Capital Partners and Readystate Asset Management. This increased confidence comes as the company approaches a critical FDA PDUFA goal date of April 10, 2026, for its lead skin cancer candidate, RP1, which could be a transformative event for the biotech firm. Replimune is well-capitalized with $269.1 million in cash, expected to fund operations into 2027, regardless of the FDA's decision.
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know
Shares of Replimune Group (REPL) could see a 65.7% upside based on the mean price target of Wall Street analysts, which stands at $12.86. Despite potential biases in analyst price targets, the agreement among analysts predicting better earnings, coupled with a Zacks Rank #2 (Buy), suggests a legitimate reason to expect an upside. Investors are advised to consider price targets with skepticism but note the strong correlation between positive earnings estimate revisions and stock price movements.
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Replimune Group (NASDAQ:REPL) carries debt but also holds significant net cash, suggesting a seemingly safe balance sheet from a liquidity perspective. However, the company is not yet profitable, burning through cash and incurring losses, which raises concerns about its need to secure additional capital in the near future. While the balance sheet appears liquid, the lack of consistent free cash flow and operating revenue makes it a higher-risk investment, pending the success of new product development.
Replimune burns cash as April 10 RP1 FDA action date approaches
Replimune reported fiscal Q3 2026 results, showing a net loss of $70.9 million and a cash balance decrease to $269.1 million, though the cash runway is extended into late Q1 2027. The company's lead product, RP1, has an FDA PDUFA target action date of April 10, 2026, for its BLA resubmission, with commercial readiness underway. Positive market reaction followed the news, boosting REPL shares by 5.81%, reflecting investor interest in the regulatory timeline and positive clinical updates for RP1 and RP2.
Piper Sandler Maintains 'Overweight' Rating for REPL, Raises PT to $14 | REPL Stock News
Piper Sandler has reaffirmed an 'Overweight' rating for Replimune Group (REPL) and increased its price target from $13.00 to $14.00, indicating a positive outlook. This adjustment follows several other analyst upgrades and price target revisions. Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer, with an average analyst target price of $12.86.
Replimune Secures Financial Runway Through 2027
Replimune Group Inc. has significantly strengthened its financial position, projecting an operational cash runway through the first quarter of 2027 following an improved fiscal third-quarter performance and an amended credit facility. The company's focus is now firmly on the upcoming FDA regulatory decision for its lead candidate, RP1, with a PDUFA action date set for April 10, 2026. Preparations for commercial launch are underway, alongside continued progress in its broader clinical pipeline.
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD)
Analysts have issued neutral ratings for Replimune Group (REPL) and ACADIA Pharmaceuticals (ACAD), suggesting neither a bullish nor bearish outlook. For Replimune Group, J.P. Morgan maintained a Hold rating with an average price target of $11.50, representing a 63.6% upside. Meanwhile, Morgan Stanley set a Hold rating for ACADIA Pharmaceuticals with a $25.00 price target, and the general Street consensus is a Moderate Buy with a $31.31 average price target.
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD)
Analysts have adopted a neutral stance on healthcare stocks Replimune Group (REPL) and ACADIA Pharmaceuticals (ACAD), issuing "Hold" ratings. J.P. Morgan's Anupam Rama maintained a Hold on Replimune Group with an average price target indicating a 63.6% upside, and Morgan Stanley's Sean Laaman did the same for ACADIA Pharmaceuticals, with an average price target suggesting a 21.9% upside. This indicates that while analysts see potential, they are not strongly bullish on these stocks at present.
Replimune Group, Inc. SEC 10-Q Report
Replimune Group, Inc. has released its Form 10-Q report for Q3 2025, detailing a loss from operations of $(71.9) million and a net loss of $(70.9) million due to increased R&D costs. The report highlights progress in RP1 clinical trials, including the IGNYTE and ARTACUS trials, and the resubmission of a Biologics License Application for RP1 for advanced melanoma with a PDUFA date of April 10, 2026. The company is also developing RP2 and RP3 and expects current cash to fund operations for at least 12 months.
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Replimune Group, Inc. announced its fiscal third quarter 2026 financial results, highlighting the FDA's acceptance of the Biologics License Application resubmission for RP1 in advanced melanoma, with a target action date of April 10, 2026. The company has also amended its loan agreement, extending its cash runway into the first quarter of 2027. Clinical trial updates for RP1 and RP2 showcased promising results in various cancers, while financial figures indicated increased R&D expenses and a net loss for the quarter.
RP1 melanoma setback and SEC probe weigh on Replimune (NASDAQ: REPL)
Replimune (NASDAQ: REPL) reported a widened net loss of $240.7 million for the nine months ended December 31, 2025, primarily due to increased R&D and S&GA expenses for its oncolytic immunotherapy pipeline. The company faces a setback with its lead product candidate, RP1, after the FDA issued a complete response letter in July 2025 for its advanced melanoma BLA, though a resubmission has been accepted with a new PDUFA date of April 10, 2026. Additionally, Replimune is addressing a putative securities class action, shareholder derivative suits, and an SEC investigation related to the RP1 BLA.
Wedbush Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price
Wedbush has increased its price target for Replimune Group (NASDAQ:REPL) to $19.00 from $18.00, maintaining an "outperform" rating and implying a potential upside of over 161%. This positive forecast follows Replimune's recent EPS beat of ($0.77) versus the consensus ($0.85). The stock, currently trading at $7.26, has an average "Hold" rating and a consensus target price of $9.88 from ten analysts.
Replimune Group, Inc. Updates on RP1 and RP2 Programs
Replimune Group, Inc. announced new data for its RP1 and RP2 programs at the J.P. Morgan Healthcare Conference, highlighting a near-term PDUFA date for melanoma treatment and commercial launch preparations. The company's trials show promise in expanding treatment beyond skin cancer with successful deep injections, and it reported $269.2M in cash. This update signifies potential advancements in its therapeutic pipeline.
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Replimune stock has surged by nearly 131% over the past three months, driven by excitement surrounding its lead drug candidate, RP1. Clinical trial results presented at SITC 2023 showed that RP1, used in combination with nivolumab, achieved high response rates in patients with metastatic melanoma, cutaneous squamous cell carcinoma, and CSCC. The company is poised to submit a Biologics License Application (BLA) in the first half of 2024, with potential FDA approval by the end of 2024 or early 2025.
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Replimune Group's stock has surged 131.1% in three months due to positive regulatory news, specifically the FDA's acceptance of the resubmitted biologics license application for its lead candidate, RP1, for advanced melanoma. This resubmission addresses previous concerns and provides a clear path forward with a target action date of April 10, 2026. The company has also reported encouraging data from other studies involving RP1 in combination with Bristol Myers' Opdivo for various skin cancers.
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL
Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. (NASDAQ: REPL) after the FDA deemed the IGNYTE trial inadequate, leading to a significant stock drop. Investors who suffered losses between November 22, 2024, and July 21, 2025, are encouraged to contact the firm, with a lead plaintiff deadline of September 22, 2025. The lawsuit alleges that Replimune overstated the trial's prospects, resulting in false and misleading statements to investors.
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 1:30 PM PT. A webcast will be available on their website, with a replay accessible for 30 days. The company, based in Woburn, MA, specializes in developing novel oncolytic immunotherapies using its proprietary RPx platform.
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. (Nasdaq: REPL) announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 1:30 PM PT. A live webcast will be available on their website, with a replay accessible for 30 days. The company focuses on developing novel oncolytic immunotherapies for cancer treatment.
